{"DataElement":{"publicId":"2986573","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor Platinum-Based Treatment Regimen Chemosensitivity Type","preferredDefinition":"A description of the sensitivity of the testicular carcinoma to any platinum-containing chemotherapeutic agent that was administered.","longName":"2986554v1.0:2961482v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2986554","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor Platinum-Based Treatment Regimen Chemosensitivity","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor. -- 2004_Derived from or containing platinum._A treatment plan that specifies the dosage, the schedule, and the duration of treatment._Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","longName":"2986052v1.0:2986552v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2986052","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor. -- 2004","longName":"C9063","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Testicular Germ Cell Tumor","conceptCode":"C9063","definition":"A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D112249-82D8-E0FD-E040-BB89AD432FCB","latestVersionIndicator":"Yes","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-13","modifiedBy":"ONEDATA","dateModified":"2010-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2986552","version":"1","preferredName":"Platinum-Based Treatment Regimen Chemosensitivity","preferredDefinition":"Derived from or containing platinum.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.:Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","longName":"C25620:C15697:C71488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Platinum-Based","conceptCode":"C25620","definition":"Derived from or containing platinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemosensitivity","conceptCode":"C71488","definition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D112249-89E9-E0FD-E040-BB89AD432FCB","latestVersionIndicator":"Yes","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-13","modifiedBy":"ONEDATA","dateModified":"2010-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2842596","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919 ","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63D982FA-DFBF-58C7-E040-BB89AD433E84","latestVersionIndicator":"Yes","beginDate":"2009-02-26","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-26","modifiedBy":"CURTIST","dateModified":"2009-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D112249-89FA-E0FD-E040-BB89AD432FCB","latestVersionIndicator":"Yes","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-13","modifiedBy":"KUMMEROA","dateModified":"2020-12-16","changeDescription":". 2020-12-16 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2961482","version":"1","preferredName":"Solid Tumor Chemosensitivity Type","preferredDefinition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors._Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better._Something distinguishable as an identifiable class based on common qualities.","longName":"S_TUMR_CHEMO_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Sensitive","valueDescription":"Sensitive","ValueMeaning":{"publicId":"3131006","version":"1","preferredName":"Sensitive","longName":"3131006","preferredDefinition":"Greater than or equal to 50 percent reduction in bidimensional diameter of all disease sites with no new sites of disease.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E310A94-443C-DD37-E040-BB89AD4337F5","latestVersionIndicator":"Yes","beginDate":"2010-08-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"ONEDATA","dateModified":"2010-08-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E310A94-4454-DD37-E040-BB89AD4337F5","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"ONEDATA","dateModified":"2010-08-19","deletedIndicator":"No"},{"value":"Not assessed, or chemotherapy less than 2 cycles","valueDescription":"Not assessed, or chemotherapy less than 2 cycles","ValueMeaning":{"publicId":"3131004","version":"1","preferredName":"Not assessed, or chemotherapy less than 2 cycles","longName":"3131004","preferredDefinition":"Not assessed, or chemotherapy less than 2 cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E310A94-43F6-DD37-E040-BB89AD4337F5","latestVersionIndicator":"Yes","beginDate":"2010-08-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E310A94-440F-DD37-E040-BB89AD4337F5","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"ONEDATA","dateModified":"2010-08-19","deletedIndicator":"No"},{"value":"Resistant","valueDescription":"Resistant","ValueMeaning":{"publicId":"3131005","version":"1","preferredName":"Resistant","longName":"3131005","preferredDefinition":"Less than 50 percent reduction in diameter of all disease sites or development of new disease sites.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E310A94-4419-DD37-E040-BB89AD4337F5","latestVersionIndicator":"Yes","beginDate":"2010-08-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E310A94-4432-DD37-E040-BB89AD4337F5","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"ONEDATA","dateModified":"2010-08-19","deletedIndicator":"No"},{"value":"Untreated, or treated greater than 6 months prior to transplant","valueDescription":"Untreated, or treated greater than 6 months prior to transplant","ValueMeaning":{"publicId":"3131022","version":"1","preferredName":"Untreated, or treated greater than 6 months prior to transplant","longName":"3131022","preferredDefinition":"Untreated, or treated greater than 6 months prior to transplant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E310A94-448B-DD37-E040-BB89AD4337F5","latestVersionIndicator":"Yes","beginDate":"2010-08-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E310A94-44A4-DD37-E040-BB89AD4337F5","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"ONEDATA","dateModified":"2010-08-19","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87982A1E-4C54-FAA5-E040-BB89AD435B6C","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-27","modifiedBy":"ONEDATA","dateModified":"2010-05-27","deletedIndicator":"No"},{"value":"Untreated","valueDescription":"Negation Therapy","ValueMeaning":{"publicId":"3061597","version":"1","preferredName":"Negation Therapy","longName":"3061597","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84902434-A37B-9A05-E040-BB89AD431C3A","latestVersionIndicator":"Yes","beginDate":"2010-04-19","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2010-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87982A1E-4C68-FAA5-E040-BB89AD435B6C","beginDate":"2010-04-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-27","modifiedBy":"ONEDATA","dateModified":"2010-05-27","deletedIndicator":"No"},{"value":"Refractory","valueDescription":"Refractory","ValueMeaning":{"publicId":"3117283","version":"1","preferredName":"Refractory","longName":"3117283","preferredDefinition":"Progression of disease within 4 weeks of last Cisplatin dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A6D16BF-6B57-B018-E040-BB89AD432A62","latestVersionIndicator":"Yes","beginDate":"2010-07-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A6D16BF-6B70-B018-E040-BB89AD432A62","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-07-02","modifiedBy":"ONEDATA","dateModified":"2010-07-02","deletedIndicator":"No"},{"value":"Chemotherapy was only given as adjuvant to the primary surgery or radiation therapy","valueDescription":"Chemotherapy was only given as adjuvant to the primary surgery or radiation therapy","ValueMeaning":{"publicId":"3361678","version":"1","preferredName":"Chemotherapy was only given as adjuvant to the primary surgery or radiation therapy","longName":"3361678","preferredDefinition":"Chemotherapy was only given as adjuvant to the primary surgery or radiation therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B736A379-70C1-37F3-E040-BB89AD4345C4","latestVersionIndicator":"Yes","beginDate":"2012-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B736A379-70DA-37F3-E040-BB89AD4345C4","beginDate":"2012-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-23","modifiedBy":"ONEDATA","dateModified":"2012-01-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2961481","version":"1","preferredName":"Solid Neoplasm Chemosensitivity Type","preferredDefinition":"Cancer of body tissues other than blood, bone marrow, or the lymphatic system.:Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.:Type; a subdivision of a particular kind of thing.","longName":"C9292:C71488:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chemosensitivity","conceptCode":"C71488","definition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AC8450-53B6-BCA8-E040-BB89AD4336B8","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-18","modifiedBy":"ONEDATA","dateModified":"2009-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AC8450-53C7-BCA8-E040-BB89AD4336B8","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-18","modifiedBy":"KUMMEROA","dateModified":"2012-06-18","changeDescription":".Added alt defs for form 2022. AK 6/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964899","version":"1","longName":"2022r1: Testicular / Germ Cell Cancer Pre-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"tc_base_sens_plt_chemo_kn","type":"NMDP_FN","context":"NHLBI"},{"name":" PerformedClinicalInterpretation:value","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Indicate the :","type":"Preferred Question Text","description":"Indicate the :","url":null,"context":"NHLBI"},{"name":"BRIDG mapping for CDE:2986573","type":"BRIDG Mapping Path","description":"PerformedDiagnosis [primary] > AssessedResultRelationship > PerformedObservation [assessment] > PerformedClinicalInterpretation.value [assessment] WHERE PerformedDiagnosis.value = \"testicular carcinoma\"  AND PerformedObservation [assessment] > PerformedObservation > DefinedObservation.name = \"Assess Chemotherapy Sensitivity\" AND DefinedObservation > DefinedSubstanceAdmininstration [focal context procedure of administration of plantinum-containing chemo agent]","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D112249-8A13-E0FD-E040-BB89AD432FCB","latestVersionIndicator":"Yes","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-13","modifiedBy":"KUMMEROA","dateModified":"2020-12-16","changeDescription":". 2020-12-16 ak OK to release per WZ. System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}